For decades, one of the most persistent and debated drawbacks of routine breast cancer screening has been the concept of overdiagnosis. This occurs when mammograms identify slow-growing or harmless cancers that would never have caused symptoms, required treatment, or threatened a woman’s life during her lifetime. Without screening, these tumors would have remained entirely unknown. However, a major new reanalysis of historical data indicates that the true scale of this phenomenon may be significantly lower than previously feared, fundamentally shifting how medical experts understand the long-term impact of mammography programs.
For generations, researchers, public health officials, and international medical communities have wrestled with conflicting statistics regarding how frequently overdiagnosis occurs. Estimates derived from randomized controlled trials have differed sharply over the years, with some influential studies suggesting that anywhere from 30% to 50% of all breast cancers detected through routine screening might fall into the category of overdiagnosis. These high figures have heavily influenced global discussions, shaping clinical guidelines, policy decisions, and the way healthcare providers communicate the delicate balance between the undeniable benefits of early detection and the potential harms of unnecessary medical interventions.
Now, an international team of researchers has revisited these foundational trials in an effort to bring clarity to the debate. By pooling and meticulously reanalyzing the evidence from all major randomized controlled trials, the research team has arrived at a much different conclusion.
"The aim of our study was to bring together the evidence from all randomized controlled trials to get a clearer picture of the extent of overdiagnosis in breast cancer screening," says Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebælt Hospital.
She notes that while randomized trials have historically been cited as primary evidence that overdiagnosis is a substantial and widespread problem, the new findings reveal that interpreting this data is far more complex than previously assumed. According to the research, the additional breast cancer cases detected during these randomized trials closely mirror real-world patterns observed in Denmark, where the rate of overdiagnosis associated with organized screening programs is estimated to be well below 5%.
A New Look at Mammography Trials
To untangle the complexities of the historical data, the research team combined and reanalyzed the results of all major randomized trials of mammography screening ever conducted. To contextualize these findings, they compared the trial data against robust, contemporary population data from Denmark, which served as a reliable real-world reference point.
Denmark offered a unique epidemiological advantage because organized, population-based breast cancer screening was introduced in some regions 17 years earlier than in others. This phased implementation created a natural experiment, allowing researchers to track precisely how breast cancer diagnosis rates shifted immediately after screening was introduced and how those patterns evolved over much longer periods.
When a screening program is first rolled out, there is an inevitable, temporary surge in the number of breast cancer diagnoses. This happens because mammography detects existing cancers earlier than they would have appeared symptomatically on their own. Over time, this initial spike should theoretically be followed by a noticeable drop in diagnoses, as many of the cancers found early would otherwise have been diagnosed at a later date.
However, this expected downward curve can be heavily obscured by external variables. For instance, women in both trial and control groups often continue to undergo opportunistic screening after official trials have concluded.
"When screening is introduced, the number of breast cancer diagnoses initially rises because cancers are detected earlier than they would have been without screening," explains Elsebeth Lynge, professor emerita at the Department of Public Health at the University of Copenhagen. "Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later. This pattern can also be affected if women in either group continue to undergo screening after the trials had ended, which was common. If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis."
By comparing breast cancer incidence rates at matching points in time across both the historical randomized trials and Denmark’s routine, modern screening programs, the research team was able to determine whether the underlying epidemiological patterns were consistent. Their analysis demonstrated striking similarities that shed entirely new light on the true scale of the issue.
"Taken together, we believe some previous high estimates of overdiagnosis, which influenced screening guidelines and communication, were based on evidence before trial data had fully matured," says Matejka Rebolj, a senior epidemiologist at Queen Mary University of London. "When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%."
Understanding Overdiagnosis and the Impact of Timing
To grasp why previous estimates varied so drastically, experts emphasize the critical role that timing plays in epidemiological studies. When mammography screening is initiated in a population, it fundamentally alters the timeline of when a cancer is discovered.
By capturing tumors at a pre-symptomatic stage, screening produces a front-loading effect, creating an immediate, visible rise in diagnostic counts. Because a portion of those detected cancers would eventually have been found organically as they grew large enough to cause symptoms, diagnosis rates should naturally decline in subsequent years as those future cases are shifted forward in time.
If a scientific study or clinical trial is cut short—ending before enough calendar time has passed for that expected post-peak decline to manifest—researchers can easily misinterpret the early surge in diagnoses as permanent overdiagnosis. Furthermore, contamination between study arms, such as when women in designated control groups seek out mammograms independently outside the trial protocol, can further distort the numbers.
The new comprehensive analysis demonstrates that accounting for these intricate timing effects and long-term trends dramatically alters the calculations. It suggests that mammography identifies harmless, non-threatening cancers far less frequently than long-standing dogma has suggested.
What Overdiagnosis Means for Women and Public Health
For women navigating complex decisions about whether to participate in routine breast cancer screening programs, understanding the accurate balance of benefits and potential harms is vital. Informed consent relies heavily on clear, realistic communication from the medical community.
While the vast majority of women will never develop breast cancer in their lifetimes, public health advocates hope these findings will alleviate unnecessary anxiety surrounding the risks of diagnostic over-intervention.
"Most women will not develop breast cancer, but with this study we can now be reassured that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment," says Sisse Helle Njor. "With this in mind, we hope this study will provide a framework for a more realistic interpretation of the evidence and help us better inform women when they are invited for screening."
The scope of the new research is extensive, encompassing a re-evaluation of all eight major randomized controlled trials ever conducted in the field of mammography screening. This historic body of research includes the New York Health Insurance Plan trial, the Malmö trials, the Two-County trial in Sweden, the Edinburgh trial, the Canadian National Breast Screening Study, the Stockholm trial, the Gothenburg trial, and the UK Age trial.
In addition to integrating data from these landmark international studies, the researchers utilized two distinct regional screening programs in Denmark as a contemporary baseline, closely tracking both invasive breast cancer and ductal carcinoma in situ (DCIS).
By carefully adjusting for differences in long-term screening exposure, follow-up duration, and the temporal dynamics of cancer detection across these diverse cohorts, the team arrived at their definitive conclusion: overdiagnosis is a minor factor in organized screening programs rather than the systemic flaw once feared by critics.
Financial support for the research was provided by prominent scientific organizations, with Casper Urth Pedersen backed by the Novo Nordisk Foundation and Matejka Rebolj supported by Cancer Research UK.
